You are here
Phase 3 Study of Altropane To Differentiate Parkinsonian From Non-Parkinsonian Tremors
"We are looking forward to completing this pivotal study and filing our first NDA as soon as possible thereafter. We believe that Altropane has the potential to meet a growing medical need for an early, objective diagnosis of tremor in the increasing elderly population, which in turn represents a substantial market opportunity for the Company", stated Dr. Marc Lanser, President and Chief Scientific Officer of BLSI. "The accurate differentiation of Parkinsonian from non-Parkinsonian tremors has important clinical implications in terms of initiating effective treatment, minimizing unnecessary treatment side-effects (by reducing the number of inappropriately treated patients), and providing a more accurate prognosis for patients and their families (since Parkinsonian tremors have a relatively poor prognosis compared to non-Parkinsonian tremors). If successful, Altropane would represent the first in a new class of "molecular targeting" diagnostic agents that has the potential ability to assist the clinician in making this important differentiation," added Dr. Lanser.
Source: Boston Life Sciences, Inc.